It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The fungus Candida albicans is an opportunistic pathogen that can exploit imbalances in microbiome composition to invade its human host, causing pathologies ranging from vaginal candidiasis to fungal sepsis. Bacteria of the genus Lactobacillus are colonizers of human mucosa and can produce compounds with bioactivity against C. albicans. Here, we show that some Lactobacillus species produce a small molecule under laboratory conditions that blocks the C. albicans yeast-to-filament transition, an important virulence trait. It remains unexplored whether the compound is produced in the context of the human host. Bioassay-guided fractionation of Lactobacillus-conditioned medium linked this activity to 1-acetyl-β-carboline (1-ABC). We use genetic approaches to show that filamentation inhibition by 1-ABC requires Yak1, a DYRK1-family kinase. Additional biochemical characterization of structurally related 1-ethoxycarbonyl-β-carboline confirms that it inhibits Yak1 and blocks C. albicans biofilm formation. Thus, our findings reveal Lactobacillus-produced 1-ABC can prevent the yeast-to-filament transition in C. albicans through inhibition of Yak1.
Alterations of the mucosal microbiota, including Lactobacillus bacteria, are associated with infections caused by the fungus Candida albicans. Here, MacAlpine et al. show that some Lactobacillus strains produce a small molecule that blocks C. albicans filamentation and biofilm formation, and thus virulence, through inhibition of a fungal kinase.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
2 University of Toronto, Department of Biochemistry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
3 Center of Excellence in Oral and Craniofacial Biology, Louisiana State University Health Sciences Center School of Dentistry, New Orleans, USA (GRID:grid.64337.35) (ISNI:0000 0001 0662 7451)
4 University of Minnesota Medical School, Department of Microbiology and Immunology, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657)
5 University of Toronto, BioZone, Department of Chemical Engineering and Applied Chemistry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Center for Structural Genomics of Infectious Diseases (CSGID), Chicago, USA (GRID:grid.17063.33)
6 University of Wisconsin School of Medicine and Public Health, Department of Medicine, Madison, USA (GRID:grid.14003.36) (ISNI:0000 0001 2167 3675); University of Wisconsin, Department of Medical Microbiology and Immunology, Madison, USA (GRID:grid.14003.36) (ISNI:0000 0001 2167 3675)
7 University of Michigan Medical School, Department of Microbiology and Immunology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
8 Rosell Institute for Microbiome and Probiotics, 6100 Avenue Royalmount, Montreal, Canada (GRID:grid.214458.e)
9 University of Toronto, BioZone, Department of Chemical Engineering and Applied Chemistry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Center for Structural Genomics of Infectious Diseases (CSGID), Chicago, USA (GRID:grid.17063.33); University of Calgary, Department of Microbiology, Immunology and Infectious Diseases, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)